How to Oppose a Pharmaceutical Patent From Germany in 2026: EPO & National Routes

Pharmaceutical patent opposition germany is the practical starting point for any competitor seeking to clear a blocking patent, secure freedom to operate, or accelerate market entry ahead of a rival’s exclusivity. The core rule to fix in the diary immediately: an EPO opposition must be filed within nine months of the mention of grant, while a German nullity action before the Federal Patent Court (Bundespatentgericht) can be lodged after grant, subject to the procedural rules of the German Patent Act. In 2026, sharpened commercial pressure, driven by ongoing German drug pricing and reimbursement reform, has increased the incentive for generic and biosimilar entrants to challenge secondary patents earlier and more aggressively.

This guide sets out both routes, the evidence you must assemble, realistic timelines and costs, and how to choose between the EPO, the Bundespatentgericht and the Unified Patent Court (UPC). It is general information, not legal advice; obtain tailored counsel before acting.

Overview, When to challenge a pharmaceutical patent

The decision to launch a pharmaceutical patent opposition germany strategy is rarely academic. It is driven by a commercial objective: to remove a legal obstacle standing between your product and the market. The most common triggers are securing freedom to operate (FTO) before committing to launch, clearing a blocking patent asserted against you, or invalidating a secondary patent, a formulation, dosage regimen, salt, polymorph or second-medical-use claim, that extends protection beyond the expiry of the original compound patent.

Secondary patents are where the majority of pharmaceutical disputes now play out. Originators layer them around a molecule to create a protective thicket, and each layer is a potential target for revocation. A well-timed challenge can shift a launch date forward by months or years, which in a high-volume therapeutic area translates directly into revenue.

Supplementary Protection Certificates (SPCs) and regulatory exclusivities also shape the timing calculus. An SPC can extend the effective monopoly of the underlying patent for a limited additional period as set by the SPC Regulation, and data or market exclusivity can independently delay a generic. These are separate rights that follow their own revocation procedures, but they interact closely with any patent attack, attacking the base patent may indirectly weaken a dependent SPC. Map the full exclusivity landscape before committing resources; the interplay between patent, SPC and regulatory protection often determines whether a challenge is worth mounting at all.

Eligibility, Who can file, standing and limits

One of the attractions of the EPO route is that any person may file an opposition against a granted European patent under Article 99 of the European Patent Convention (EPC). There is no requirement to demonstrate a commercial interest or standing. This permits the use of a strawman opponent, a filing made in the name of a professional representative or a shell entity, where a challenger wishes to keep its identity confidential. That said, the EPO scrutinises abuse of the strawman device, so the arrangement must be structured carefully.

German nullity actions (Nichtigkeitsklage) before the Bundespatentgericht (BPatG) are similarly open: any person may bring an action for revocation of a German patent or the German part of a European patent, without a formal standing requirement. The action is directed to the court and, if successful, revokes or limits the patent with effect for Germany.

The critical distinction lies in remedies and geographic scope. An EPO opposition affects the European patent centrally, revocation removes the patent in all designated states at once, and maintenance in amended form binds every national part. A German nullity action affects only the German designation, but it delivers a directly enforceable national outcome and sits alongside the German infringement courts that can grant or lift injunctions. Choose the forum according to whether you need broad central relief or focused national enforcement leverage.

Step-by-step: pharmaceutical patent opposition germany at the EPO and starting a German nullity action

There are two parallel pathways, and they are not mutually exclusive. The EPO opposition delivers central revocation of the European patent; the German nullity action delivers enforceable national relief. Many pharmaceutical challengers run both, or stage them, to preserve options and maximise pressure. The steps below set out each pathway in sequence, with tactical notes specific to pharmaceutical and biological subject matter.

EPO opposition pathway

1. Step 1, Prior-art and risk assessment (Opponent counsel and technical experts; 1–6 weeks). Run a full patent-family and regulatory-data search across patent databases, scientific and clinical literature, conference abstracts, product dossiers and regulatory filings. Identify the novelty and inventive-step gaps in the granted claims. Where the strongest attack turns on reproducibility or a technical effect, plan replication experiments early. Be mindful of the admissibility of regulatory documents, you may need certified translations and a protocol for handling confidential material.
2. Step 2, Prepare grounds and gist of attack (Opponent counsel; 2–4 weeks). The available grounds under Article 100 EPC are lack of novelty and lack of inventive step (patentability grounds), insufficiency of disclosure, and added subject-matter. For pharmaceuticals, inventive step is frequently decisive, for example, the obviousness of a dosage regimen or a formulation over the prior art. Insufficiency is a powerful attack against complex biologicals, where the specification may not enable the full breadth of the claim.
3. Step 3, Draft the opposition notice (Opponent counsel; 1 week). The notice must identify the patent, state the extent to which it is opposed, set out each ground relied on, and provide a reasoned statement of the facts and evidence supporting each ground, with annexes. A clear summary of reasons at the outset helps the Opposition Division follow the attack.
4. Step 4, File the opposition at the EPO (Opponent counsel; up to the deadline). File the notice and pay the opposition fee before nine months elapse from the mention of grant in the European Patent Bulletin. This deadline is strict, see the timeline section below.
5. Step 5, Case management at the EPO (Opponent counsel and experts; 1–3+ years). Written rounds follow: the patentee responds, the opponent files observations, and the patentee may propose amended claim sets (auxiliary requests). Oral proceedings before the Opposition Division are usual in contested pharmaceutical cases. Expect a total case length in the region of 18–36 months, and longer if the decision is appealed to the Technical Boards of Appeal.
6. Step 6, Enforcement and coordination with national proceedings (Coordinating counsel; as needed). Throughout, plan for parallel national enforcement. A German infringement court can grant an injunction while the EPO opposition is pending, so anticipate injunction risk and consider a national nullity action or a stay application to manage it.

German nullity action pathway

1. Step A, Pre-action clearance and urgency assessment (In-house counsel and German litigation counsel; 1–2 weeks). If a competitor’s marketing is imminent or an injunction has been threatened, national action may be the more direct route to national relief. Assess the urgency and the injunction exposure before choosing your forum. Note that under German procedure a nullity action against the German part of a European patent generally cannot be brought while an EPO opposition remains pending or the opposition period is still running.
2. Step B, Draft and file the nullity action at the Bundespatentgericht (German counsel; 2–4 weeks). The action (Nichtigkeitsklage) must set out the grounds for revocation, the supporting evidence, and the request. The German Patent Act (Patentgesetz) governs the substantive grounds and the procedure.
3. Step C, Case management and evidence (German counsel and the court; 12–36 months). The BPatG typically issues a preliminary opinion (qualifizierter Hinweis) that frames the oral hearing. Injunctive relief and infringement are handled separately by the regional infringement courts, so coordinate the nullity timeline with any parallel infringement proceedings.
4. Step D, Appeal (Parties; months to years). A first-instance BPatG decision may be appealed to the Federal Court of Justice (Bundesgerichtshof, BGH), which resolves the key points of law. Factor the appeal window into your commercial planning.

Tactical integration of the two routes

Running both routes can maximise coverage and preserve options, but it introduces coordination and timing constraints. Two points demand attention:

• Consistency of the attack. Keep the grounds and prior-art combinations aligned across the EPO and the BPatG. Divergent positions can be exploited by the patentee and undermine credibility before either tribunal.
• Claim-amendment coordination. The patentee may amend claims at the EPO. Track those amendments so your national attack targets the correct claim set, and avoid arguments in one forum that concede ground in the other.

The evidence strategy underpins both routes and, for pharmaceuticals, is often the decisive factor, it is addressed in its own section below.

Step / Who / Duration timeline

Required documents and evidence checklist

The strength of a pharmaceutical patent opposition germany filing lives or dies on the quality of its evidence. Assemble the file methodically: procedural documents to open the case, prior-art documents to substantiate the grounds, and technical evidence to prove the point. The table below sets out the core items, their purpose and the practical handling notes.

Special subsection, evidence handling for biologicals

Biologicals raise evidence problems that small-molecule cases rarely encounter. Sufficiency of disclosure is often the battleground: whether the specification enables a skilled team to make and use the full breadth of the claimed antibody, cell line or fusion protein, or whether it leaves an undue burden of experimentation. Expect the tribunal to lean heavily on common general knowledge and on expert testimony to bridge gaps in the written description.

Three practical issues recur. First, judges and technical members frequently need a tutorial on the underlying biology, prepare clear, well-structured expert reports that teach as well as argue. Second, the most probative evidence often sits inside regulatory dossiers (marketing authorisation applications, clinical trial reports) that are commercially sensitive. Third, sequence listings, cell-line characterisation and manufacturing data must be presented in an admissible form. The tactical answer is a confidentiality protocol combined with redacted regulator submissions and anonymised expert reports, so that the substance is before the tribunal without exposing confidential business information.

Timeline and deadlines

The single most important deadline is the EPO opposition period. Under Article 99(1) EPC, an opposition may be filed within nine months of the publication of the mention of grant in the European Patent Bulletin. Miss it and the central opposition route closes permanently, the only remaining avenues are national revocation actions. Diarise the grant date the moment it appears, and build in a comfortable buffer for evidence assembly, translations and internal sign-off.

German nullity actions carry no equivalent short cut-off, but they are subject to an important sequencing rule: a Nichtigkeitsklage against the German part of a European patent generally cannot be brought while EPO opposition proceedings are pending or while the opposition period is still running. Once that constraint falls away, timing is driven by commercial rather than statutory factors: preliminary injunction windows, the progress of parallel infringement proceedings, and the commercialisation timeline of your product all press on when the action should be started. In practice, urgency, not a fixed deadline, dictates the timing of a national challenge.

For the interaction of these windows across both routes, refer back to Table 1, which sets out the practical duration of each phase.

Costs and funding

Pharmaceutical challenges are among the most expensive patent disputes because of the technical complexity and the reliance on experiments and expert evidence. Budget realistically and stage your spend. The figures below are indicative ranges in euros; verify the official EPO, DPMA and Bundespatentgericht fee schedules at the point of filing, as they are periodically revised.

Note that German court fees and statutory lawyers’ fees in nullity and infringement proceedings are calculated by reference to the value in dispute (Streitwert), which can be substantial in pharmaceutical cases. The losing party generally bears a proportion of the winning party’s statutory costs. Fund the exposure sensibly: options include third-party litigation funding, conditional fee arrangements where permitted, after-the-event insurance, and portfolio-level budgeting across a group of related challenges. The most cost-disciplined approach is staged spend: commission a limited prior-art search and a written opinion first, use it to triage the case, and escalate to full evidence-gathering and filing only where the merits justify it.

What changes in 2026

The 2026 backdrop matters for strategy. Legislative measures aimed at stabilising the finances of the statutory health insurance system, with implications for drug pricing and reimbursement, have been under active discussion in Germany, and tighter reimbursement economics tend to reward those who reach the market first. That dynamic sharpens the incentive to clear blocking and secondary patents earlier. Verify the status and content of any specific reform before relying on it, as legislative measures may still be in the parliamentary process.

On the procedural side, check the EPO’s and the Bundespatentgericht’s current practice notices before filing, as electronic-filing requirements and case-management practice are periodically updated. The Unified Patent Court, operational since 1 June 2023, continues to develop its case law on revocation and injunctions, which increasingly influences forum choice. Confirm live fee figures and any procedural amendments at the point of filing rather than relying on historical guidance.

Strategic forum choice: EPO opposition vs German nullity vs UPC

Choosing the forum is the most consequential tactical decision in any pharmaceutical patent opposition germany campaign. The three routes differ in scope, speed, remedy and cost. The table below compares them; the guidance that follows explains when each is the right instrument.

In practice the decision flow is straightforward. Choose the EPO opposition where the objective is central revocation of the European patent at a controlled cost and within the nine-month window. Choose the German nullity action where immediate national enforcement matters or where you face injunction risk in Germany and need a national revocation to defend your launch. Consider the UPC where the patent carries unitary effect or is a European patent that has not been opted out, and where broad, central relief across contracting states fits your commercial geography, and take specialist UPC advice before committing, because the transitional rules and opt-out mechanics require careful handling.

Common pitfalls and mitigation

• Missing the nine-month EPO deadline. The single most damaging error. Mitigate by diarising the grant date the instant the mention of grant publishes and building in a buffer for translations and internal approvals.
• Underestimating replication costs for biologics. Lab work on complex molecules can run into six figures. Mitigate by scoping and budgeting the experimental programme at the earliest planning stage, not mid-proceedings.
• Leaking confidential regulatory data. Regulatory dossiers are powerful evidence but sensitive. Mitigate with a confidentiality protocol, redaction and anonymised expert summaries agreed with the tribunal.
• Inconsistent parallel filings. Divergent positions across the EPO and the BPatG hand the patentee an advantage. Mitigate by coordinating grounds, prior-art combinations and responses to claim amendments across both forums under one lead counsel.
• Poor expert selection. An expert who cannot withstand cross-examination or teach the tribunal weakens the whole case. Mitigate by engaging domain experts with genuine court and hearing experience.

Examples and tactical checklists

Use the following quick checklist as the backbone of any pharmaceutical patent opposition germany project:

1. Diarise the grant date and confirm the nine-month EPO opposition expiry.
2. Run a full patent-family and regulatory-data search.
3. Prepare the core grounds, novelty, inventive step, insufficiency, added matter.
4. Assemble the expert team and scope any replication experiments early.
5. File the opposition and/or nullity action within the relevant window, observing the sequencing rules between the EPO and the BPatG.
6. Plan enforcement and injunction-defence steps in parallel across jurisdictions.

Conclusion

A disciplined pharmaceutical patent opposition germany strategy comes down to a handful of decisions taken early and executed precisely: fix the nine-month EPO deadline in the diary, decide whether central revocation, national enforcement leverage, or both best serve your commercial objective, invest in high-quality expert and experimental evidence for biologicals, and coordinate parallel filings so they reinforce rather than undermine each other. The 2026 pricing environment has raised the commercial stakes, and the challengers who prepare their evidence and forum choice methodically will be best placed to clear obstacles and reach the market first. For a tailored case triage on a specific patent, contact us through the Global Law Experts pharmaceutical practice to plan your next step.

This article is for general information only and does not constitute legal advice.

Further reading and related services: Pharmaceutical lawyers Germany (practice & contact), Intellectual property lawyer Germany (hiring & fees guide), and the author profile at Dr. Anke Krebs, author profile & contact.

Sources

1. European Patent Office (EPO)
2. European Patent Convention (EPC), texts and articles
3. EPO Guidelines for Examination
4. Deutsches Patent- und Markenamt (DPMA)
5. Bundespatentgericht (BPatG)
6. Bundesgerichtshof (BGH)
7. German Patent Act (Patentgesetz)
8. Unified Patent Court (UPC)
9. Max Planck Institute for Innovation and Competition